Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ari Ciment

Pulmonary Disease Miami Beach, FL Medical Doctor

NPI 1932261542 CMS profile 133603

4302 Alton Rd, Suite 210, Miami Beach, FL 33140

Open in the dashboard

General payments

$24,147

251 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ari Ciment of Miami Beach, FL is reported in the CMS Open Payments database as having received $24,147 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,082 41
2024 General $1,035 43
2023 General $9,452 72
2022 General $3,908 38
2021 General $514 22
2020 General $2,771 11
2019 General $2,384 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ari Ciment
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Ari Ciment were reported at $4,082. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Ari Ciment Pulmonary Disease median Middle half National median
2019 $2,384 $377 $109–$1,340 $163
2020 $2,771 $230 $56–$907 $114
2021 $514 $269 $68–$1,072 $132
2022 $3,908 $390 $100–$1,457 $149
2023 $9,452 $419 $114–$1,659 $160
2024 $1,035 $476 $123–$1,818 $164
2025 $4,082 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vapotherm Inc $14,552 15 payments
  2. Mylan Specialty L.P. $4,650 8 payments
  3. GlaxoSmithKline, LLC. $1,574 79 payments
  4. AstraZeneca Pharmaceuticals LP $622 32 payments
  5. Actelion Pharmaceuticals US, Inc. $571 18 payments
  6. AbbVie, Inc. $320 12 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $294 11 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $243 15 payments
  9. Amgen Inc. $164 9 payments
  10. Grifols USA, LLC $143 7 payments
  11. Other $1,014 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $14,405 9 payments
  2. Food and Beverage $5,007 236 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,568 3 payments
  4. Education $168 3 payments
Products named General payments · program years 2019–2025
  1. Vapotherm Respiratory $7,742 5 payments
  2. VAPOTHERM Respiratory $6,810 10 payments
  3. Yupelri $4,623 7 payments
  4. TRELEGY ELLIPTA $722 40 payments
  5. UPTRAVI $571 18 payments
  6. NUCALA $536 34 payments
  7. AREXVY $430 16 payments
  8. FASENRA $390 20 payments
  9. OPSUMIT $334 9 payments
  10. AVYCAZ $270 10 payments
  11. Other $2,840 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

602

Median for Pulmonary Disease: 936

Drug cost

$272,062

Median for Pulmonary Disease: $487,987

Branded share of claims

61%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zemaira Alpha-1-Proteinase Inhibitor Brand 14 $113,331
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 105 $88,577
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 45 $31,328
Breo Ellipta Fluticasone/Vilanterol Brand 33 $15,048
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 23 $11,766
Symbicort Budesonide/Formoterol Fumarate Brand 19 $4,797
Ventolin Hfa Albuterol Sulfate Brand 28 $1,731
Albuterol Sulfate Hfa Albuterol Sulfate Brand 73 $1,420
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 15 $1,197
Wixela Inhub Fluticasone Propion/Salmeterol Brand 12 $632

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$116,652

Medicare's payments for the services billed

Medicare patients

404

Average age 77

Services billed

1,200

200 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 52%
COPD 46%
Heart failure 44%
Chronic kidney disease 41%
Diabetes 39%
Atrial fibrillation 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $308
$308 105 —
AREXVY
  • GlaxoSmithKline, LLC. $217
$217 — —
TEZSPIRE
  • Amgen Inc. $54
  • AstraZeneca Pharmaceuticals LP $30
$84 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $68
$68 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record